How have JAGX shares performed in 2023?

Jaguar Health's stock was trading at $0.0869 at the beginning of the year. Since then, JAGX shares have increased by 205.1% and is now trading at $0.2652. View the best growth stocks for 2023 here .

Are investors shorting Jaguar Health?

Jaguar Health saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 827,900 shares, a decrease of 26.1% from the October 31st total of 1,120,000 shares. Based on an average trading volume of 4,860,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.3% of the company's shares are short sold. View Jaguar Health's Short Interest .

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our JAGX earnings forecast .

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) released its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.38) earnings per share for the quarter. The biotechnology company had revenue of $2.81 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 1,191.67% and a negative net margin of 370.40%.

When did Jaguar Health's stock split?

Jaguar Health's stock reverse split before market open on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , Vaxart (VXRT) , Purple Biotech (KTOV) , Onconova Therapeutics (ONTX) , Tonix Pharmaceuticals (TNXP) , Biopharmx (BPMX) , Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT) .

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX)

$0.27

-0.02 (-7.01%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.27
▼
$0.29
50-Day Range: $0.23
▼
$0.46
52-Week Range: $0.21
▼
$9.53

Volume: 2.66 million shs
Average Volume: 4.72 million shs
Market Capitalization: $13.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Jaguar Health MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.24
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.83) to ($0.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.34 out of 5 stars

Medical Sector

897th out of 942 stocks

Pharmaceutical Preparations Industry

429th out of 448 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Jaguar Health.

5.0

Short Interest

Percentage of Shares Shorted
2.27% of the float of Jaguar Health has been sold short.
Short Interest Ratio / Days to Cover
Jaguar Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Jaguar Health has recently decreased by 26.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Jaguar Health does not currently pay a dividend.
Dividend Growth
Jaguar Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JAGX.

1.8

News and Social Media Coverage

News Sentiment
Jaguar Health has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Jaguar Health this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jaguar Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.16% of the stock of Jaguar Health is held by insiders.
Percentage Held by Institutions
Only 12.24% of the stock of Jaguar Health is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Jaguar Health are expected to grow in the coming year, from ($5.83) to ($0.40) per share.

See Top Rated MarketRank™ Stocks Here

About Jaguar Health Stock (NASDAQ:JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

JAGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JAGX Stock News Headlines

December 8, 2023 | morningstar.com

Jaguar Health Inc JAGX

December 8, 2023 | americanbankingnews.com

Jaguar Health (NASDAQ:JAGX) Now Covered by Analysts at StockNews.com

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 7, 2023 | finance.yahoo.com

MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company

December 6, 2023 | finance.yahoo.com

Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website

December 4, 2023 | msn.com

FDA renews conditional approval for Jaguar canine chemo drug

December 4, 2023 | finance.yahoo.com

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

December 1, 2023 | americanbankingnews.com

Jaguar Health (NASDAQ:JAGX) Coverage Initiated by Analysts at StockNews.com

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 30, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference

November 30, 2023 | finance.yahoo.com

Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference

November 22, 2023 | msn.com

Jaguar Health falls after update on Phase 3 trial for plant-based drug

November 21, 2023 | msn.com

Jaguar Health’s stock drops after results supporting ‘paramount’ trial have not been received yet

November 21, 2023 | finance.yahoo.com

Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming

November 15, 2023 | finance.yahoo.com

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call Transcript

November 15, 2023 | finance.yahoo.com

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

November 14, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health Reports Third Quarter 2023 Financial Results

November 14, 2023 | finance.yahoo.com

Jaguar Health Reports Third Quarter 2023 Financial Results

November 13, 2023 | benzinga.com

Earnings Preview For Jaguar Health

November 9, 2023 | finance.yahoo.com

Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium

November 7, 2023 | finance.yahoo.com

REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST

November 2, 2023 | finance.yahoo.com

Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets

November 1, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

November 1, 2023 | finance.yahoo.com

Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

October 30, 2023 | finance.yahoo.com

Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet

October 26, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health to Present November 1st at Emerging Growth Conference

October 26, 2023 | finance.yahoo.com

Jaguar Health to Present November 1st at Emerging Growth Conference

See More Headlines

Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JAGX
CUSIP: N/A
CIK: 1585608
Web: www.jaguaranimalhealth.com
Phone: (415) 371-8300
Fax: N/A
Employees: 60
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,450,000.00
Net Margins: -370.40%
Pretax Margin: -380.79%
Return on Equity: -1,191.67%
Return on Assets: -79.95%

Debt

Debt-to-Equity Ratio: 22.00
Current Ratio: 1.77
Quick Ratio: 1.10

Sales & Book Value

Annual Sales: $11.96 million
Price / Sales: 1.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.32) per share
Price / Book: -0.83

Miscellaneous

Outstanding Shares: 50,760,000
Free Float: 50,675,000
Market Cap: $13.46 million
Optionable: Not Optionable
Beta: 1.68

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Ms. Lisa A. Conte (Age 64)
Founder, CEO, President & Director
Comp: $771.4k
Dr. Pravin R. Chaturvedi Ph.D. (Age 60)
Chief Scientific Officer & Chair of Scientific Advisory Board
Comp: $539.04k
Mr. Jonathan S. Wolin CPA (Age 60)
J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel
Comp: $520.29k
Mr. Ian H. Wendt M.B.A. (Age 55)
Chief Commercial Officer
Comp: $441.31k
Dr. Steven R. King Ph.D. (Age 65)
Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
Comp: $477.66k
Ms. Carol R. Lizak M.B.A. (Age 59)
Chief Financial Officer
Mr. Peter Hodge
Senior Director of Investor Relations, Business Development & Special Events
Dr. Karen J. Brunke Ph.D. (Age 71)
Executive VP of Corporate & Business Development
Mr. David Sesin
Chief Manufacturing Officer

Key Competitors

View All Competitors

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed in 2023?: Jaguar Health's stock was trading at $0.0869 at the beginning of the year. Since then, JAGX shares have increased by 205.1% and is now trading at $0.2652.
View the best growth stocks for 2023 here.
Are investors shorting Jaguar Health?: Jaguar Health saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 827,900 shares, a decrease of 26.1% from the October 31st total of 1,120,000 shares. Based on an average trading volume of 4,860,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.3% of the company's shares are short sold.
View Jaguar Health's Short Interest.
When is Jaguar Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our JAGX earnings forecast.
How were Jaguar Health's earnings last quarter?: Jaguar Health, Inc. (NASDAQ:JAGX) released its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.38) earnings per share for the quarter. The biotechnology company had revenue of $2.81 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 1,191.67% and a negative net margin of 370.40%.
When did Jaguar Health's stock split?: Jaguar Health's stock reverse split before market open on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).
When did Jaguar Health IPO?: (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
Who are Jaguar Health's major shareholders?: Jaguar Health's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Jaguar Health?: Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:JAGX) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX)